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Abstract: The chloroform extract of Valeriana wallichii (V. wallichii) rhizomes was 
investigated to elucidate the structures responsible for reported antileishmanial activity. 
Besides bornyl caffeate (1, already been reported by us previously), bioassay-guided 
fractionation resulted in two additional cinnamic acid derivatives 2–3 with moderate 
leishmanicidal activity. The structure of a novel nepetolactone derivative 4 having a 
cinnamic acid moiety was elucidated by means of spectral analysis. To the best of our 
knowledge villoside aglycone (5) was isolated from this plant for the first time. The 
bioassay-guided fractionation yielded two new (compounds 6–7) and two known valtrates 
(compounds 8–9) with leishmanicidal potential against Leishmania major (L. major) 
promastigotes. In addition, β-bisabolol (10), α-kessyl alcohol (11), valeranone (12), bornyl 
isovalerate (13) and linarin-2-O-methylbutyrate (14) were identified. This is the first report 
on the isolation of 4'-demethylpodophyllotoxin (15), podophyllotoxin (16) and pinoresinol 
(17) in V. wallichii. In total thirteen known and four new compounds were identified from 
the extract and their cytotoxic and antileishmanial properties were evaluated.  
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1. Introduction 
Valeriana wallichii DC (syn. V. jatamansi Jones) is endemic to the Himalayan regions of India, Nepal 
and China and is used in folk and ayurvedic medicine, for instance, against sleep disorders, skin disorders 
or pain [1]. Antimicrobial [2], anti-inflammatory [3], insecticidal [4], antiviral [5] and antioxidant [6,7] 
properties of the extract are known. Additionally, the antileishmanial activity of the chloroform extract 
of the rhizomes was reported previously [8] and studies to isolate and identify the responsible 
compounds by bioassay-guided fractionation were undertaken and produced bornyl caffeate (1) [9]. In 
continuation of our search for antileishmanial compounds in V. wallichii we herein reveal the 
antileishmanial activity of valtrates and we isolated additional cytotoxic compounds which are to date 
unheard in Valeriana. We successfully isolated and characterized two more cinnamic acid derivatives 2, 
3 showing leishmanicidal properties. Additionally, we discovered a nepetolactone derivative 4 and 
villoside aglycone 5, both being novel natural products. Two new (compounds 6–7) and two known 
valtrates (compounds 8–9) were found. For all valtrates we could show strong antileishmanial activity. 
Furthermore, β-bisabolol (10), α-kessyl alcohol (11), valeranone (12), bornyval (13), linarin-O-2-
methylbutyrate (14), 4'-demethylpodophyllotoxin (15), podophyllotoxin (16) and pinoresinol (17) were 
isolated from the extract (cf. Figure 1). 
2. Results and Discussion 
2.1. Bioassay-Guided Fractionation of the Extract 
The dried chloroform extract of V. wallichii rhizomes was slurried in MeOH, filtered and fractionated 
into 12 fractions F1–F12 by preparative HPLC. After screening for antileishmanial activity on L. major 
promastigotes in vitro the most promising fractions F4–F8 were further investigated by subjecting them 
to preparative HPLC and multiple column chromatographic separations (cf. Figure 2) which led to the 
isolation and identification of highly active valtrates 6–9 and cinnamic acid derivatives 1–3 with 
moderate antileishmanial activity. β-Bisabolol (10) and valeranone (12) were found in a subfraction of 
F7 and bornyl isovalerate (13) and α-kessyl alcohol (11) were isolated from fraction F8. The non-active 
fractions F1–F3 gave the highest amount of substances. To avoid missing small amounts of potentially 
active compounds we have carefully investigated these fractions. This resulted in the discovery of a 
novel cinnamic acid derivative 4 with a nepetolactone skeleton and villoside aglycone 5. From these 
fractions 4'-demethylpodophyllotoxin (15), podophyllotoxin (16), pinoresinol (17) and linarin-O-2-
methylbutyrate (14) were isolated as well (cf. Figure 1). 
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Figure 1. Isolated and identified compounds from V. wallichii extract. Abbr.: Iv = isovaleryl; 
Miv = β-methylisovaleryl; IvaIva = α-isovaleroyloxyisovaleryl; Ac = acetyl. 
 
Molecules 2015, 20 5743 
 
 
Figure 2. Overview of the bioassay-guided fractionation of V. wallichii extract. Method A: 
preparative HPLC (250 mm × 10 mm, 5 µm, Nucleosil 100-5); H2O (a): MeOH (b), gradient: 
70% b (0 min), 75% b (7 min), 100% b (25 min), 70% b (30 min); flow rate: 3.3 mL/min. 
Method B: preparative HPLC (125 mm × 10 mm, 5 µm, Nucleodur Sphinx RP); H2O (a): 
CH3CN (b), gradient: 10% b (0–2 min), 30% b (2–15 min), 65% b (15–22 min), 10% b (22–
24 min); flow rate: 4.4 mL/min. Method C: flash chromatography (silica gel; MeOH/CHCl3, 
4.8:0.2, v/v). Method D: column chromatography (silica gel; MeOH/CHCl3, 4.8:02, v/v). 
2.2. Structure Elucidation of Novel Nepetolactone Derivative 4 
Compound 4 was isolated as a yellowish syrup after multiple fractionation of F1. The IR spectrum 
showed absorption bands for hydroxyl groups (3382 cm−1), carbonyl functions (1749 and 1697 cm−1) 
and a double bond (1603 cm−1). The ESI-MS investigation yielded mass signals at m/z 506.9 [M−H]−, 
621.4 [M−H+TFA]− and 326.8 [M−Glc]− in the negative mode, respectively, supporting the proposed 
structure. In the positive mode multiple adducts (526.2 [M+H3O]+, 531.1 [M+Na]+) were detected 
besides the molecular ion signal at m/z 509.0 [M+H]+. Fragmentation of m/z 526.2 and 531.1 gave a 
fragment of m/z 347.1 [M−Glc+Na]+. In the NMR spectra the characteristic 1H and 13C signals for a 
trans-cinnamic acid with a para-substituted phenyl ring were present. 13C signals in the range of  
70–80 ppm represented a sugar moiety. The assignment of the sugar as β-D-glucose was supported by 
comparison of the coupling constants of the protons to data from the literature [10] while the connectivity 
of the sugar and the cinnamic acid derivative to the nepetolactone skeleton [11] was established by 
HMBC cross peaks. Interpretation of coupling constants and NOESY experiments revealed the 
stereochemistry (cf. Figure 3): NOESY correlations of H-8 with other protons were the most prominent 
ones. H-8 gave NOESY cross peaks with H-1' of the sugar moiety, H-10, H-2" and H-3" of the cinnamic 
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acid rest and the H-11 protons of the methyl group which led to the conclusion that all these groups are 
in close spatial proximity. The cinnamic acid seems to be located in the space above H-8. Therefore the 
proposed configuration is consistent with the configuration of the villoside aglycone 5 and other similar 
compounds from Valeriana [12]. Additional evidence came from a weak NOESY correlation between 
the protons of the C-9 methyl group and H-5b. Thus, compound 4 was assigned to be {[(3S,4S,7R,8S)-
1-oxo-3,7-dimethyl-4-(O-β glucopyranosyl)oxy]hexahydrocyclopenta-[c]furan-3-yl}-methyl-trans-4-
hydroxycinnamate. 
 
Figure 3. Key 1H-1H-COSY, HMBC and NOESY correlations of 4. 
2.3. Structure Elucidation of Villoside Aglycone 5 
Villoside is an iridoid glycoside first isolated by Taguchi et al. [13] from Patrinia villosa Juss., a 
Valerianaceae. However, the villoside aglycone was only obtained semi-synthetically [13]. This is the 
first report on the isolation of the aglycone 5 directly from a plant, after chromatographic separation of 
F1 (cf. Figure 2). Similar compounds (jatamanines) have been isolated from V. jatamansi before [12]. 
Compound 5 was obtained as a yellow syrup. The IR spectrum is characterized by absorption bands at 
3387 cm−1 indicating a hydroxyl group and at 1,705 cm−1 caused by a carbonyl function. The ESI-MS 
showed signals at m/z 185.1 [M+H]+ and 207.0 [M+Na]+ which was consistent with the calculated mass 
of m/z 184.1 for the proposed structure. The 1H spectrum did not show any aromatic proton signals. The 
13C spectrum exhibited ten signals including a typical signal for a lactone functionality at 175.7 ppm. A 
13C signal at 19.8 ppm with a corresponding 1H signal at 1.13 ppm for three protons suggested the 
presence of a methyl group (C-11). The methylene groups next to an oxygen gave characteristic 13C 
signals at 61.7 and 68.7 ppm (C-3 and C-10, respectively). The remaining signals were found in the 
aliphatic region. The 1H-1H COSY data showed the presence of a spin system involving the hydrogens 
H-5 to H-9 and, therefore, suggested the presence of a 5-membered ring. All signals have been fully 
assigned by means of 1H-1H COSY, HMBC and HMQC experiments. The configuration was determined 
by using coupling constants and NOESY data (cf. Figure 4). NOESY correlations between H-11 and H-
9, H-5 and H-10, respectively, suggested the methyl group (C-11) and the proton at C-9 as well as the 
methylene group at C-10 and the proton at C-5 to be located in the same plane of the molecule. The 
small coupling constant of H-4 and H-3b (3.2 Hz) supports this hypothesis of a quasi-equatorial position 
of H-4. Additionally, the coupling constant between H-9 and H-8 (Jaa = 8.1 Hz) was backing a trans-
configuration. Furthermore, the coupling constant between H-5 and H-9 (11.0 Hz) was consistent with 
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the reported values of the structurally similar jatamanines having the same configuration [12]. Taking 
biogenetic reasons into account, compound 5 can be assigned to (4R,5S,8R,9S)-4-(hydroxymethyl)-8-
methylhexahydro-cyclopenta[c]pyranone (villoside aglycone). 
 
Figure 4. Key 1H-1H-COSY, HMBC and NOESY correlations of villoside aglycone 5. 
2.4. Valtrates with Antileishmanial Activity  
Typical and well known constituents of Valeriana species are iridoid esters e.g., of the valepotriate 
and valtrate type, which have been previously investigated in detail because of their in vitro  
antifungal [14] and cytotoxic activity [15–17] and their potential use as antitumor agents [18]. In the 
active fractions F4–F7 two known valtrates were found, one (compound 8) of the diene- and one 
(compound 9) of the hydrine-type [16], and two iridoid esters 6, 7 with an as yet unreported substitution 
pattern. The known valtrates were identified by comparing their spectral data to the literature data (cf. 
Table 1). Compound 8 has been reported before [14,19,20] and valechlorine (9) too [17,21,22]. The new 
compounds consist of a typical valtrate skeleton of the hydrine-type and are esterified with various acids 
e.g. isovaleric acid, acetic acid. The connections of the esters were assigned by HMBC experiments (cf. 
Figure 5). By comparing coupling constants and taking biogenetic considerations into account the 
configuration was determined to be the same as reported in the literature. 
Most of the terpenes have been found in subfractions of F7 and F8 (cf. Figure 2). β-Bisabolol (10) [23], 
α-kessyl alcohol (11) [24,25], valeranone (12) [26] and bornyl isovalerate (13) are well known in the 
Valeriana species [27–30] since a plethora of terpenes has been identified from the essential oil of 
Valeriana, especially by GC/MS analysis [31,32] in the past. Linarin-O-2-methylbutyrate (14) has been 
reported from V. wallichii before [33]. Additionally the following known natural products were isolated 
from V. wallichii for the first time: the phenylpropanoids caffeic (1), isoferulic (2) and  
p-hydroxycinnamic acid bornyl ester (3), the lignans 4 -´demethylpodophyllotoxin (15), podophyllotoxin 
(16) and pinoresinol (17).  
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Table 1. 1H- and 13C-NMR data of new and known valtrates 6–9 in CDCl3. 
 Position 13C of 6 1H of 6 13C of 7 1H of 7 13C of 8 [20] 1H of 8 13C of 9 [17] 1H of 9 [17] 
 1 89.2 6.22 (d; 4.7; 1H) 89.2 6.27 (d; 4.2; 1H) 92.5 6.25 (d; 10.0; 1H) 89.4 6.19 (d; 5.1; 1H) 
 3 141.0 6.44 (br s; 1H) 140.9 6.44 (br s; 1H) 148.0 6.68 (br s; 1H) 141.0 6.45 (br s; 1H) 
 4 112.8  112.9  108.7  113.0  
 5 31.8 2.90 (dd; 9.2; 11.0; 1H) 31.4 2.90 (dd; 7.8; 8.0; 1H) 139.1  32.6 2.91 (m; 1H) 
 6 34.9 2.1 (m; 2H) 34.7 2.12 (m; 2H) 117.6 5.77 (t; 2.8; 1H) 35.0 2.04–2.13 (m; 2H) 
 7 80.1 4.99 (t; 4.5; 1H) 80.4 5.03 (t; 4.7; 1H) 83.1 5.47 (d; 2.8; 1H) 80.0 5.01 (t; 3.9; 1H) 
 8 80.9  80.9  80.2  81.8  
 9 44.5 2.42 (dd; 6.1; 15.0; 1H) 44.7 2.44 (dd; 4.1; 9.6; 1H) 48.4 2.94 (dd; 2.5; 10.0; 1H) 45.4 2.45 (dd; 5.9; 8.1; 1H) 
 10 66.8 
4.29 (d; 11.5; 1H) 
4.35 (d; 11.5; 1H) 
66.6 4.22 (s; 2H) 65.5 
4.32 (d; 11.6; 1H) 
4.39 (d; 11.6; 1H) 
49.1 
3.71 (d; 11.4; 1H) 
3.82 (d; 11.4; 1H) 
 11 63.4 
4.42 (d; 12.3; 1H) 
4.62 (d; 12.3; 1H) 
63.3 
4.42 (d; 12.3; 1H) 
4.62 (d; 12.3; 1H) 
60.9 
4.64 (d; 12.5; 1H) 
4.71 (d; 12.5; 1H) 
63.3 
4.42 (d; 12.3; 1H) 
4.60 (d; 12.3; 1H) 
R1 1 171.3  171.1  170.8 d  171.1  
 2 41.3 2.40 (m; 2H) 43.3 b 2.23 (m; 4H) 43.2 2.32 (d; 7.0; 2H) 43.4 g 2.09–2.13 (m; 4H) 
 3 31.8 1.90 (m; 1H) 25.6 c 2.07–2.15 (m; 3H) 25.7 2.05–2.09 (m; 2H) 25.7 h 2.00–2.06 (m; 2H) 
 4 19.5 0.97 (m; 3H) 22.3 a 0.96 (m; 18H) 22.3 f 0.93 (d; 6.6; 6H) g 22.4 i 0.97 (d; 6.7; 6H) g 
 5 29.3 1.40 (m; 2H) 22.3 a 0.96 (m; 18H) 22.3 f 0.93 (d; 6.6; 6H) g 22.4 i 0.97 (d; 6.7; 6H) g 
 6 11.2 0.90 (m; 3H)       
R2 1 169.7  173.0  170.8 d   172.9  
 2 43.0 2.30–2.35 (m; 4H) 43.5 2.19 (m; 2H) 20.9 2.04 (s; 3H) 43.3 g 2.09–2.13 (m; 4H) 
 3 25.7 2.11 (m; 2H) 25.7 c 2.07–2.15 (m; 3H)   25.6 h 2.00–2.06 (m; 2H) 
 4 and 5 22.4 0.98 (d; 6.9; 12H) 22.4 a 0.96 (m; 18H)   22.4 i 0.95 (d; 6.6; 6H) g 
R3 1 170.2  170.3  171.8  169.8  
 2 21.0 2.07 (s; 3H) 21.0 2.05 (s; 3H) 43.4 2.14 (m; 2H) 21.0 2.08 (s; 3H) 
 3     25.6 e 2.05–2.09 (m; 2H)   
 4 and 5     22.3 f 0.95 (d; 6.6; 6H) g   
R4 1 173.2  172.9  173.8    
 2 76.9 4.74 (d; 4.8; 1H) 43.1 b 2.23 (m; 4H) 43.0 2.20 (m; 2H)   
 3 30.0 2.23 (m; 1H) 25.7 c 2.07–2.15 (m; 3H) 25.6 e 2.17–2.25 (m; 1H)   
 4  18.8 1.02 (m; 3H) 22.3 a 0.96 (m; 18H) 22.3 f 0.99 (d; 6.6; 6H) g   
 5 17.3 1.00 (m; 3H) 22.3 a 0.96 (m; 18H) 22.3 f 0.99 (d; 6.6; 6H) g   
 6 172.9        
 7 43.0 2.30–2.35 (m; 4H)       
 8 25.7 2.11 (m; 2H)       
 9 and 10 22.4 0.98 (d; 6.9; 12H)       
a–i Assignments may be interchanged. 
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Figure 5. Key HMBC correlations of valtrates 6 and 7. 
2.5. Antileishmanial Activity and Cytotoxicity  
All compounds isolated were subjected to the evaluation of their antileishmanial activity against  
L. major promastigotes in vitro and cytotoxicity against macrophages (J774.1 murine cell line) using the 
corresponding AlamarBlue© assays [34] (cf. Table 2).  
Table 2. Antileishmanial activity and cytotoxicity of fractions containing isolated compounds. 
Compound 
IC50 (L. major) 
[µg/mL] 
IC50 (J774.1) 
[µg/mL] 
Bornyl caffeate (1) 48.8 * 8.3 * 
2 16.7 34.7 
3 12.2 8.6 
4 >100 >100 
5 >100 17.5 
6 1.9 a <0.8 a 
7 0.8 <0.8 
8 1.7 * 1.0 * 
9 2.3 1.9 
β-Bisabolol (10) 52.2 37.1 
α-Kessyl alcohol (11) 5.8 b 1.7 b 
Valeranone (12) 60.8 42.6 
Bornyl isovalerate (13) >100 * >100 * 
Linarin-O-2-methylbutyrate (14) >100 10.8 
15 >100 <0.8 
16 >100 <0.8 
Pinoresinol (17) >100 <0.8 
Miltefosine 36.2 * 56.5 * 
* These data were gained from pure or synthesized compounds and are therefore given in µM. a There was a 
small amount of another valtrate present. b The fraction of kessyl alcohol was contaminated with an non-identified 
valtrate (~10% by NMR integration). 
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The valtrates 6–9 showed the highest antileishmanial activity (IC50 0.8–2.3 µg/mL). Their 
cytotoxicity is in the same range. It is unknown whether the cytotoxicity is directly responsible for the 
leishmanicidal potential. Nevertheless, the valtrates represent the main active principle of the extract. 
Fractions with moderate antileishmanial activity in the range of the standard drug miltefosine were 
phenylpropanoids bornyl caffeate (1), bornyl isoferulate (2) and bornyl 3-hydroxycinnamate (3). This 
has led to the synthesis of a compound library and QSAR studies recently reported by us [2].  
Furthermore, valeranone (12) and β-bisabolol (10) exhibited moderate antileishmanial and cytotoxic 
activity. The kessyl alcohol fraction showed rather good antileishmanial activity. However, it was 
contaminated with an active but unidentified valtrate, thus it remains unclear whether kessyl alcohol (8) 
is really active. Bornyl isovalerate (13), linarin-O-2-methylbutyrate (14), podophyllotoxin (11),  
4'-demethylpodophyllotoxin (15) and pinoresinol (16) showed no antileishmanial activity. However, 
podophyllotoxin and 4'-demethylpodophyllotoxin were highly cytotoxic (IC50 < 0.8 µg/mL). This is not 
surprising as podophyllotoxin and derivatives are widely used as anticancer agents. However, 
cytotoxicity and antileishmanial activity are not linked to each other in this case. Fractions with novel 
compounds 4 and 5 exhibited no antileishmanial activity (IC50 > 100 µg/mL). Nevertheless, villoside 
aglycone (5) showed moderate cytotoxicity (IC50 17.5 µg/mL). Taken together the antileishmanial 
activity was found in valtrate derivatives, mainly, and cinnamic acid derivatives with exception of novel 
compound 4. However the valtrates were found to be highly cytotoxic in contrast to the cinnamic acid 
derivatives having moderate cytotoxicity. 
3. Experimental Section  
3.1. General 
1H (400.132 MHz), 13C (100.613 MHz) and 2D NMR spectra were recorded on a Bruker Avance 400 
Ultra Shield™ (Bruker Biospin, Ettlingen, Germany) spectrometer. As internal standard the signals of 
the deuterated solvents were used (CDCl3: 1H 7.26 ppm, 13C 77.0 ppm). IR spectra were recorded on a 
Jasco FT/IR-6100 spectrometer (Groß-Umstadt, Germany) with an ATR unit at room temperature. 
LC/MS was conducted on an Agilent 1100 analytical HPLC with DAD detection and an Agilent 
LC/MSD Trap (Agilent Technologies, Böblingen, Germany). For flash chromatography a Reveleris 
Flash system (Grace, Columbia, MD, USA) was used. Preparative HPLC was conducted using an 
Agilent 1100 preparative HPLC with fraction collector and multiple wavelength detector (MWD). TLC 
plates (60 F254) were purchased from Macherey-Nagel. Column chromatography was carried out on 
silica gel (Kieselgel 60, 0.063–0.2 mm, 70–320 mesh, Merck, Darmstadt, Germany), filtration on 
LiChroprep© RP-18 (40–63 µm, Merck). 
3.2. Plant Material 
Dried rhizomes of V. wallichii were acquired from a local herb shop in Kolkata, India. The identity 
as V. jatamansi Jones syn. V. wallichii DC. was confirmed by comparison with an authentic sample 
cultivated at the Institute of Himalayan Bioresource Technology in Palampur, Himachal Pradesh, India 
by R.D. Singh. A voucher specimen of the herbarium was preserved in the laboratory of Banasri Hazra 
(IHBT Ref. No. 11666). 
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3.3. Extraction and Isolation 
The pulverized rhizome (10 g) was refluxed with chloroform (100 mL) for 2 h and filtered. The 
solvent was removed from the filtrate in a rotary evaporator, followed by complete drying in vacuo. 
Thus, the chloroform extract was obtained (yield = 1.1%; w/w) and preserved at 4 °C. The process was 
repeated to get higher amounts of the extract as per experimental requirements. Dry extract (11 g) was 
slurried in MeOH and filtrated using a short column filled with LiChroprep RP-18 silica gel which 
yielded 9.5 g of extract after evaporation. This material was fractionated into 12 fractions (F1–F12) by 
preparative HPLC method A (250 mm × 10 mm, 5 µm, Macherey-Nagel Nucleosil 100-5; A) H2O, B) 
MeOH, gradient: 70% B (0 min), 75% B (7 min), 100% B (25 min), 70% B (30 min); flow rate:  
3.3 mL/min).  
A portion of 600 mg of fraction F1 was further fractionated by preparative HPLC method B  
(125 mm × 10 mm, 5 µm, Macherey-Nagel Nucleodur Sphinx RP; A) H2O, B) CH3CN, gradient: 10% 
B (0–2 min), 30% B (2–15 min), 65% B (15–22 min), 10% B (22–24 min); flow rate: 4.4 mL/min) 
resulting in 9 fractions (F1-1 to F1-9). F1-1 (1.5 mg) yielded villosid aglycone 5, F1-4 (9 mg) the novel 
nepetolactone derivative 4. From F1-5 (3.7 mg) and F1-6 (9.1 mg) podophyllotoxin (16) and  
4'-demethylpodophyllotoxin (15) were identified and F1-7 (2.9 mg) contained pinoresinol (17).  
A 150 mg portion of fraction F2 was partitioned in two fractions (F2-I and F2-II) using the above 
HPLC method B. In F2-I linarin-O-2-methylbutyrate (14) (6.0 mg) was found and F2-II (12.5 mg) 
yielded podophyllotoxin (16)  
Fractionation of F3 into three fractions (F3-I to F3-III) yielded again the linarin derivative 14 in  
F3-II. Fraction F4 was subjected to flash chromatography (silica gel, MeOH/CHCl3, 4.8:0.2 v/v) and 
gave 6 fractions (4α–4ζ) from which valechlorine (9) was identified in fraction 4γ (32.6 mg). 
Fraction F5 was separated by column chromatography (CC) on silica gel (MeOH/CHCl3, 4.8:0.2 v/v) 
and yielded 5 fractions (5α, 5β1, 5β2, 5β3, 5γ). Repeating the chromatography with fraction 5β3  
(258 mg) gave three fractions (5β3a–5β3c) of which the last fraction 5β3c yielded 135 mg of bornyl 
caffeate (1). Fractionation of 5β2 (168 mg) by CC gave four fractions (5β2a–5β2c) of which fraction 
5β2a gave 14.2 mg of valtrate 7. Fractions 5β2b and 5β2c were combined and subjected to preparative 
HPLC method B). This process resulted in six fractions (5β2bc1–5β2bc6) from which fraction 5β2bc 
yielded 6.1 mg of valtrate 9.  
Fraction F6 was again fractionated like F5 by CC which gave seven fractions 6α–6η. 6γ (24.2 mg) 
and 6δ (25.7 mg) were combined and subjected to preparative HPLC method B which gave fractions 
6dega1-6dega5. 6dega2 again yielded valtrate 7 (4.9 mg) and 6dega3 valtrate 8 (4.0 mg).  
F7 was fractionated by column chromatography as above and gave four fractions (7α–7δ). 7α (57.6 mg) 
was further partitioned by CC into four fractions (7α1–7α4) of which 7α2 yielded 1.5 mg of a mixture of 
valeranone (12) and β-bisabolol (10). Further fractionation of 7α3 (19.7 mg) by the same CC method 
gave another 3 fractions (7α3a–7α3c) of which 7α3a consisted of 5.0 mg pure β-bisabolol (10). 7α3c yielded 
2.1 mg of caffeic acid derivative 2. Fractions 7β and 7γ were combined and fractionated by preparative 
HPLC method B which resulted in 10 fractions (7bega1–7bega10) of which fraction 7bega2 gave 7.6 mg 
cinnamic acid derivative 3 and fraction 7bega9 2.5 mg of valtrate 6.  
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F8 was fractionated into 6 fractions (8α–8ζ) by CC. Fraction 8β yielded 1.7 mg of bornyl isovalerate 
(13). 8ε was fractionated further by HPLC method B and gave six fractions (8ε1–8ε6) with fraction 8ε4 
yielding 6.8 mg kessyl alcohol (11).  
3.4. Characterization of Novel Nepetolactone Derivative {[(3S,4S,7R,8S)-1-Oxo-3,7-dimethyl-4-(O-β-
D-glucopyranosyl)oxy]hexahydrocyclopenta[c]furan-3-yl}-methyl-trans-4-hydroxycinnamate (4) 
Yellowish syrup; IR (ATR): 3382 (OH); 1749, 1697 (C=O), 1603 (C=C) cm-1; 1H-NMR (CDCl3):  
δ = 1.19 (3H, d, J = 6.9 Hz, H-11), 1.73 (3H, s, H-9), 1.41 (1H, m, H-6b), 1.68 (1H, m, H-5b), 1.97 (1H, 
m, H-6a), 2.20 (1H, m, H-5a), 2.35 (1H, m, H-7), 2.83 (1H, m, H-8), 3.22 (1H, m, H-2'), 3.26 (1H, m, 
H-5'), 3.41 (1H, t, J = 9.1 Hz, H-3'), 3.50 (1H, t, J = 9.6 Hz, H-4'), 3.79 (2H, dd, J = 3.2, 7.6 Hz, H-6'), 
4.37 (1H, d, J = 7.5 Hz, H-1'), 4.52 (2H, m, H-10), 6.21 (1H, d, J = 15.9 Hz, H-2"), 6.79 (2H,  
J = 8.6 Hz, H-6", H-8"), 7.36 (2H, d, J = 8.6 Hz, H-5", H-9"), 7.60 (1H, d, J = 15.9 Hz, H-3") ppm;  
13C-NMR (CDCl3): δ = 17.1 (C-9), 21.5 (C-11), 30.6 (C-5), 33.0 (C-6), 37.6 (C-7), 59.8 (C-8), 61.3 (C-
6'), 67.3 (C-10), 69.4 (C-4'), 73.2 (C-2'), 76.0 (C-5'), 76.3 (C-3'), 86.0 (C-4), 93.4 (C-3), 96.8 (C-1'), 
113.5 (C-2"), 115.8 (C-6", C-8"), 125.7 (C-4"), 130.2 (C-5", C-9"), 146.4 (C-3"), 159.5 (C-7"), 167.5 
(C-1"), 177.2 (C-1) ppm; ESI-MS: m/z 621.4 [M−H+TFA]−, 506.9 [M−H]−, 326.8 [M−Glc]−; HRMS 
(ESI-TOF+): m/z [M+Na]+ calculated for C25H32O11Na: 531.1842; found: 531.1836. 
3.5. Characterization of Villoside Aglycone (4R,5S,8R,9S)-4-(Hydroxymethyl)-8-methylhexahydro-
cyclopenta[c]pyranone (5) 
Yellowish syrup; IR (ATR): 3387 (OH); 1705 (C=O) cm−1; 1H-NMR (CDCl3): δ = 1.11–1.18 (1H, 
m, H-7a), 1.13 (3H, d, J = 6.4 Hz, H-11), 1.21–1.31 (1H, m, H-6a), 1.63–1.72 (1H, m; H-4), 1.82–1.88 
(1H, m, H-7b), 1.97–2.05 (1H, m, H-6b), 2.12–2.27 (2H, m, H-8, H-5), 2.32 (1H, dd, J = 8.4, 11.0 Hz, 
H-9), 3.44 (1H, dd, J = 8.00, 11.1 Hz, H-10a),  3.64 (1H, dd, J = 4.70, 11.1 Hz, H-10b), 4.10 (1H, m, H-
3a), 4.35 (1H, dd, J = 3.20, 11.1 Hz, H-3b) ppm; 13C-NMR (CDCl3): δ = 19.8 (C-11), 32.3 (C-6), 34.6 
(C-7), 38.4 (C-8), 38.9 (C-5), 42.4 (C-4), 48.9 (C-9), 61.7 (C-10), 68.7 (C-3), 175.7 (C-1) ppm; ESI-MS: 
m/z 185.1 [M+H]+, 207.0 [M+Na]+; HRMS (ESI-TOF+): m/z [M+Na]+ calculated for C10H16O3Na: 
207.0997; found: 207.0993. 
3.6. Antileishmanial and Cytotoxicity Assays 
Antileishmanial activity against L. major promastigotes and cytotoxicity against a murine 
macrophage cell line (J774.1) was determined using an AlamarBlue© assay. Methods for both procedures 
have been reported previously [34]. IC50 values are presented as mean values of two experiments. 
4. Conclusions  
The valtrates 6–9 represent the main active antileishmanial principles of the V. wallichii extract, but 
they are toxic. Additionally, the cinnamic acid derivatives 1–3 showed moderate activity, interestingly 
except for novel compound 4. This could be due to the larger size of the molecule or the higher polarity 
caused by the sugar moiety. However, the previously reported cinnamic acid derivatives exhibited higher 
activity, even without the double bond [2]. 
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